FTSE MIB
33.855,69 -415,43 (-1,21%) Dow Jones
37.885,41 -575,51 (-1,50%) Nasdaq
15.417,22 -295,53 (-1,88%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,62 -0,19 (-0,23%) Bitcoin EUR
59.268,12 -2.501,10 (-4,05%)
Novo Nordisk A/S (NOVO-B.CO)
| Chiusura precedente | 878,70 |
| Aperto | 876,10 |
| Denaro | 864,90 x 0 |
| Lettera | 865,10 x 0 |
| Min-Max giorno | 853,30 - 876,10 |
| Intervallo di 52 settimane | 504,40 - 932,00 |
| Volume | |
| Media Volume | 2.752.310 |
| Capitalizzazione | 3,858T |
| Beta (5 anni mensile) | 0,19 |
| Rapporto PE (ttm) | 46,42 |
| EPS (ttm) | 18,63 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | 12,80 (1,46%) |
| Data ex dividendo | 22 mar 2024 |
| Stima target 1A | 905,68 |
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 October 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme
- GlobeNewswire
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in
FX EmpireNovo Nordisk: Relentless Inflows Send Shares Soaring
Novo Nordisk (NVO) shares are surging, up 51% in 2023. While the company recently raised its guidance due to Ozempic and Wegovy, mega demand for the stock is powering the surge.
